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Objective: To assess the cross-sectional association between depression and glucose tolerance status. Methods: We conducted a
study of 6754 White, Black, Hispanic, and Chinese men and women aged 45 to 84 years in the Multiethnic Study of Atherosclerosis
(MESA). Depression was defined as Center for Epidemiologic Studies Depression scale score of 16 and/or antidepressant use.
Glucose tolerance status was defined as normal, impaired fasting glucose (IFG) or Type 2 diabetes mellitus (untreated and treated).
Results: In the minimally adjusted model, although depression was not associated with a greater odds of IFG (odds ratio (OR) 
1.01; 95% confidence interval (CI): 0.87–1.18) or untreated diabetes (OR  1.03; 95% CI: 0.74–1.45), it was associated with a
greater odds of treated diabetes (OR  1.57; 95% CI: 1.27–1.96). This persisted following adjustment for body mass index (OR 
1.52; 95% CI: 1.22–1.90), metabolic (OR  1.54; 95% CI: 1.23–1.93), and inflammatory (OR1.53; 95% CI: 1.21–1.92) factors,
daily caloric intake and smoking (OR  1.48; 95% CI: 1.16–1.88), and socioeconomic markers (OR  1.47; 95% CI: 1.17–1.85).
Among individuals with treated diabetes, median depression scores were higher in those with microalbuminuria compared with
those without microalbuminuria (median  7; interquartile range: 3–13 versus median  6; interquartile range: 2–11; p  .046).
Depression scores were not associated with homeostatic model assessment of insulin resistance among individuals without diabetes.
Conclusions: In MESA, depression was significantly associated with treated diabetes. Further studies are needed to determine the
temporality of this association. Key words: diabetes mellitus, impaired fasting glucose, depression, epidemiology, insulin
resistance.
BMI  body mass index; CES-D  Center for Epidemiologic
Studies Depression (CES-D) scale; CI  confidence interval;
CRP  C-reactive protein; HOMA-IR  homeostatic model
assessment of insulin resistance; IFG  impaired fasting glucose;
IL-6  interleukin-6; MESA  Multiethnic Study of Atheroscle-
rosis; OR  odds ratio.
INTRODUCTION
Identification of modifiable risk factors for diabetes isimportant for its prevention. The prevalence of depression
in diabetic individuals is increased compared with in the
general population (1,2). Several studies, including one
conducted by our group, have found that the presence of
depressive symptoms is predictive of incident diabetes (3–
7), although at least one study failed to detect a longitudinal
association (8). An increased prevalence of depression in
patients with diabetes has been documented in several
ethnic groups (9 –15); however, with the exception of one
study that showed a significant association between depres-
sion and diabetes only in African-Americans (16), most
studies have found rates of depression to be similar among
diabetic individuals of different ethnicities (17–19).
Disordered carbohydrate metabolism has also been dem-
onstrated in nondiabetic individuals with depression/mood
disorders (20,21). There are several mechanisms through
which depression may lead to diabetes, including its effects
on health behaviors such as diet, physical activity, and
adherence to medications (22–25), its effects on adiposity
(26), or its influence on biological factors such as activation
of the neuroendocrine response (20,27–29) and/or inflam-
matory response (30,31). An alternative hypothesis is that a
diagnosis of diabetes leads to depression. Depression is
more likely to occur in individuals who develop new dia-
betic complications and who develop complications that
impair physical and cognitive functioning (1). A recently
published abstract found that depression was associated
with diagnosed diabetes but not with unrecognized glucose
intolerance (32).
Using data from the Multiethnic Study of Atherosclero-
sis (MESA), we examined the cross-sectional association
between depressive symptoms and diabetes in a large,
ethnically diverse group of men and women. We investi-
gated associations of depressive symptoms with various
glucose tolerance categories as well as with a measure of
insulin resistance in nondiabetic individuals. We also in-
vestigated whether these associations varied by race/eth-
nicity. Although most studies have found that the associa-
tion between depression and diabetes is similar among
different ethnicities, many studies have had smaller sample
sizes (17–19). MESA has one of the largest populations,
6000 individuals, in which to examine these and other
associations. Because MESA had data on a standardized
measure of depressive symptoms and data on health behav-
iors, socioeconomic status (SES), and metabolic (i.e., adi-
posity and lipids) and inflammatory variables, we could
determine whether this association was independent of risk
factors for Type 2 diabetes that are also strongly associated
with depression.
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METHODS
Study Population
MESA is a multicenter, longitudinal cohort study of the prevalence and
correlates of subclinical cardiovascular disease and the factors that influence
the progression of mild subclinical cardiovascular disease to severe subclin-
ical and clinical cardiovascular disease (33). Between July 2000 and August
2002, 6814 men and women who identified themselves as White, Black,
Hispanic, or Chinese, 45 to 84 years of age, and free of self-reported clinical
cardiovascular disease were recruited from six US communities: Baltimore
City and Baltimore County, Maryland; Chicago, Illinois; Forsyth County,
North Carolina; Los Angeles County, California; Northern Manhattan and the
Bronx, New York; and St. Paul, Minnesota. Details on the sampling frames
and the cohort examination procedures have been published (33). Informed
consent was obtained from the participants and the study was approved by
Institutional Review Boards of each institution.
Assessment of Exposure
Depressive symptoms were assessed using the Center for Epidemiologic
Studies Depression (CES-D) Scale, a 20-item questionnaire aimed at mea-
suring depressive symptoms in community populations (34). The items rep-
resent the major components of depression and include depressed mood,
feelings of worthlessness, feelings of hopelessness, loss of appetite, poor
concentration, and sleep disturbance. The scale does not include items for
increased appetite or sleep, anhedonia, psychomotor agitation or retardation,
guilt, or suicidal thoughts. Cronbach’s  for reliability of the instrument has
reportedly ranged between 0.84 and 0.93 (35). Participants are asked to rate
each item on a scale from 0 to 3 based on “how often you have felt this way
during the past week.” Scores ranged from 0 to 60, with higher scores
indicating more severe depressive symptoms. For our analyses, depression
was defined as a CES-D score of 16, consistent with mild-to-moderate
depression or dysthymia at the population level (36), and/or self-reported use
of antidepressant medications (tricyclics, nontricyclics, and monoamine oxi-
date inhibitors). CES-D was administered in English, Spanish, Cantonese, and
Mandarin. The reliability of the CES-D is comparable in European-American,
African-American, Mexican-American, and Chinese-American groups
(37,38). The CES-D has been used widely in cross-cultural epidemiological
studies conducted with the well-validated Spanish and Chinese versions
(39,40).
Assessment of Outcome
Participants were asked to fast for 12 hours and avoid smoking and heavy
physical activity for 2 hours before each examination. Fasting blood samples
were drawn by venipuncture from an antecubital vein into vacuum tubes.
Blood specimens were collected between 7:30 AM and 10:30 AM. Serum
samples were frozen and stored at 70°C. Details of serum sampling and
processing have been described previously (33).
Glucose tolerance status was defined according to the 2003 American
Diabetes Association criteria (41). Diabetes was defined as a fasting glucose
of 7.0 mmol/L (126 mg/dl) or use of hypoglycemic medication (oral agents
and/or insulin). Impaired fasting glucose (IFG) was defined as a fasting
glucose of 5.5 to 6.9 mmol/L (100–125 mg/dl). Diabetes was further subdi-
vided into individuals who were untreated (no pharmacological therapy) and
treated (use of oral antidiabetic agents or insulin). Individuals with untreated
diabetes who indicated that they were aware of their diagnosis were consid-
ered to have self-reported diabetes and had answered yes to the question: “Do
you have diabetes?”
Among nondiabetic individuals, insulin resistance was estimated using the
homeostasis model assessment of insulin resistance (HOMA-IR  glucose
[mmol/L]  insulin [mIU/L]/22.5) (42). Serum glucose was measured by rate
reflectance spectrophotometry using thin film adaptation of the glucose oxi-
dase method (Vitros analyzer, Johnson & Johnson Clinical Diagnostics, Inc.,
Rochester, NY) (Laboratory CV: 1.1%). Insulin was determined by a radio-
immunoassay method (Linco Human Insulin Specific RIA Kit, Linco Re-
search, Inc., St. Charles, MO). The lower limit of sensitivity is 2 U/L with a
laboratory coefficient of variation of 4.9%.
Covariates
Self-reported information included sex, age, race/ethnicity, years of edu-
cation, cigarette smoking history, and annual income. Data on prescription
and over-the-counter medication use were collected by transcription of med-
ication bottles brought into the clinic. We categorized education as a) less than
high school, b) high school, c) some college, technical school, or associates’
degree, and d) completed college or greater. Annual income was categorized
as  or $30,000. Smoking status was categorized as never, former, or
current.
Weight and height were measured using a balance beam scale and a
vertical ruler, respectively, with the participants wearing light clothing and no
shoes. Height was recorded to the nearest 0.5 cm and weight to the nearest 0.5
lb. Body mass index (BMI) was calculated as weight (kg) divided by height
squared (m2). Waist circumference was measured at the minimum abdominal
girth and the hip circumference was measured at the level of the symphysis
pubis and maximum protrusion of the buttocks. All anthropometric measures
were taken in duplicate and averaged.
Resting blood pressure was measured three times with participants in the
seated position with an automated oscillometric sphygmomanometer (Di-
namap model Pro 100, Critikon, Tampa, Florida). The average of the last two
measurements was used. Hypertension was defined as systolic pressure of
140 mm Hg, diastolic pressure of 90 mm Hg, or current use of antihy-
pertensive medication.
Total and high-density lipoprotein (HDL) cholesterol and triglycerides were
measured from blood samples obtained after a 12-hour fast. Low-density lipopro-
tein (LDL) cholesterol was calculated using the Friedewald formula (43).
Interleukin (IL)-6 was measured by ultra-sensitive ELISA (Quantikine HS
Human IL-6 Immunoassay, R&D Systems, Minneapolis, Minnesota) and
C-reactive protein (CRP) was measured using the BNII nephelometer (N High
Sensitivity CRP, Dade Behring Inc., Deerfield, Illinois). A spot urine sample
was collected from each participant, preferable in the early morning at the
beginning of the clinic visit. Urine creatinine was measured (Vitros 950IRC,
Johnson & Johnson Clinical Diagnostics, Inc., Rochester, New York) and
urine albumin was determined (Array 360 CE Protein Analyzer, Beckman
Instruments, Inc., Brea, California) (33).
The participant’s usual diet and daily caloric intake during the last year
was characterized using a 120-item food frequency questionnaire, modified
from the validated Insulin Resistance Atherosclerosis Study in which com-
parable validity was observed for non-Hispanic White, African-American,
and Hispanic individuals (44,45). The MESA dietary assessment was modi-
fied to include foods typically eaten by Chinese groups. For our analyses, total
daily caloric intake was used as the summary variable.
Analysis
The study design was a cross-sectional study in which the exposure
variable was depressive symptoms, assessed via the CES-D and/or antide-
pressant medication use, and the outcome variables were categories of glucose
tolerance status (i.e., normal, impaired fasting glucose, untreated and treated
diabetes mellitus) and insulin resistance (i.e., HOMA-IR) among individuals
without diabetes. The individuals excluded from the study had missing data
on diabetes diagnosis (n  98) or on depression (n  36), leaving 6754 study
participants.
We first examined differences in glucose tolerance status in persons with
(CES-D scale scores of 16 and/or antidepressant medication use) and
without (CES-D scale scores of 16) depression. To explore potential mech-
anisms explaining the relationship between depression and diabetes, a series
of multivariable logistic regression models were constructed to calculate the
odds ratios of IFG and treated and untreated diabetes in individuals with
depression compared with those without depression. In all of these analyses,
individuals without depression were the reference group. Glucose tolerance
categories were mutually exclusive. For each of the three glucose tolerance
categories, individuals with normal glucose tolerance were coded as 0 and
individuals with impaired fasting glucose, untreated diabetes, and treated
diabetes were coded as 1 for their respective categories. For example, in the
analyses in which the odds of untreated diabetes was determined for individ-
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uals with depression compared with those without depression, individuals
with IFG and treated diabetes were coded as missing.
In the base model, adjustments were made for age, race/ethnicity, sex, and
MESA site. We also examined changes in associations after additional ad-
justment for BMI, metabolic variables (lipids, inflammatory markers), socio-
economic (education, annual household income) and lifestyle variables
(smoking, daily caloric intake) that were significantly associated with depres-
sion in univariate analyses. In additional models in which CES-D was mod-
eled as a continuous variable, logistic regression analyses were used to
calculate the odds of IFG and untreated and treated diabetes for each 1-point
increase in CES-D score.
Linear regression models were used to determine the mean difference in
CES-D scores among individuals with IFG, untreated diabetes, and treated
diabetes compared with individuals with normal glucose tolerance. As in the
logistic regression analyses, the base model was adjusted for age, race/
ethnicity, sex, and MESA site and multivariable models were adjusted for
socioeconomic, metabolic, inflammatory, and lifestyle covariates that were
significantly associated with depression in univariate analyses.
In a separate analysis among 5790 individuals without diabetes, the
relationship between depressive symptoms and HOMA-IR was determined
using linear regression models. Because the distribution of CES-D scores and
HOMA-IR were not normally distributed, CES-D scores were divided into
quartiles and HOMA-IR was log-transformed for the purpose of analysis.
Linear regression models were then used to calculate the mean difference in
log HOMA-IR in the second, third, and fourth CES-D quartiles compared
with the first.
To examine whether diabetic individuals aware of their disease were more
likely to be depressed than those unaware, we compared CES-D scores in
untreated diabetic individuals who were and were not aware of their condi-
tion. To examine the impact of disease severity, we compared CES-D scores
in treated diabetic individuals with different types of treatment (oral agents
versus insulin) and in treated diabetic individuals with and without microalbu-
minuria (defined as a urine albumin/creatinine ratio of 30 mg/g (46). In
these analyses, the median CES-D scores were compared using Wilcoxon
rank-sum test.
Finally, we assessed for statistical interactions of depression with age, sex,
race/ethnicity, and BMI (25 kg/m2 versus 25 kg/m2) by including appro-
priate interaction terms in the regression models. Statistical interaction was
assessed using likelihood ratio tests to compare nested regression models.
Because no interactions were found, results are presented for the whole




Table 1 summarizes demographic, socioeconomic, lifestyle,
and metabolic covariates by depression status. Compared with
individuals without depression, those with depression were more
likely to be younger, White, female, current cigarette smokers, to
have a high school education or less, to have not completed
college, to have an annual income $30,000 per year, and to
have a greater daily caloric intake. Chinese-Americans had the
lowest prevalence of depression. Depression prevalence also
varied by MESA site. Depressed individuals also had greater
waist circumference, BMI, triglycerides, IL-6, and CRP than
nondepressed individuals. Surprisingly, individuals with de-
pression had lower fasting glucose (after excluding those with
diabetes), lower LDL cholesterol, and higher HDL cholesterol
than individuals without depression. In univariate analyses,
treated diabetes was more prevalent among individuals with
depression than among nondepressed individuals. The preva-
lence of depression in individuals with normal glucose toler-
ance, IFG, untreated diabetes, and treated diabetes was 18.4%,
16.2%, 15.8%, and 22.8%, respectively.
Multivariable Analyses
Multivariable models were constructed using covariates
that were significantly associated with depression in univari-
ate analyses—age, race/ethnicity, MESA site, BMI, metabolic
factors (triglycerides, HDL cholesterol, and LDL cholesterol),
inflammatory markers (IL-6 and CRP), lifestyle factors (daily
caloric intake and smoking status), and markers of SES (ed-
ucation and annual household income). These factors are also
known risk factors associated with Type 2 diabetes mellitus.
Analyses Exploring Hypothesis That Depression
Leads to Diabetes
In the base model, which was adjusted for age, race/
ethnicity, sex, and MESA site, individuals with depression did
not have a greater odds of IFG and untreated diabetes com-
pared with individuals without depression (Table 2). How-
ever, there was a 57% greater odds of having treated diabetes
in depressed individuals compared with nondepressed individ-
uals (Table 2). This association persisted following adjustment
for BMI (model 2). Our results were similar when waist
circumference was substituted for BMI. To avoid collinearity,
only BMI was included in all subsequent multivariable mod-
els. Further adjustment for inflammatory covariates (IL-6 and
CRP in model 4) did not attenuate the associations. Although
the associations were attenuated after the adjustment for met-
abolic factors (lipids in model 3; OR  1.47; 95% CI: 1.18–
1.84), lifestyle covariates (daily caloric intake and smoking
status; OR  1.48; 95% CI: 1.16–1.88) (Table 2, model 5)
and education and annual household income (as markers of
SES; OR  1.47; 95% CI: 1.17–1.85) (Table 2, model 6), they
remained statistically significant. In a fully adjusted model
that included all covariates (model 2  log triglycerides, HDL
cholesterol, LDL cholesterol, IL-6, CRP, caloric intake, smok-
ing status, education, annual income), the association between
depression and treated diabetes was attenuated but remained
significant (OR  1.38; 95% CI: 1.08–1.78).
We found similar associations within each race/ethnic
group, although the point estimates in the unadjusted model
were not all statistically significant, likely due to the smaller
sample sizes. Compared with individuals with normal glucose
tolerance, the odds of depression in those with treated diabetes
was 1.80 (95% CI: 1.15–2.82), 1.56 (95% CI: 0.71–3.40), 1.36
(95% CI: 0.92–1.97), and 1.68 (95% CI: 1.17–2.41) for White
individuals, Chinese-Americans, African-Americans, and His-
panic-Americans, respectively. There were no significant in-
teractions by race/ethnicity, age, sex, or BMI.
Because individuals taking antidepressants may have
been using them to treat other conditions, such as diabetic
neuropathy, we repeated the analyses defining depression
only as CES-D scores of 16. Although attenuated, the
result were very similar for treated diabetes: model 1
(OR  1.33; 95% CI: 1.08 –1.70), model 2 (BMI; OR 
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1.32; 95% CI: 1.02–1.69), model 3 (metabolic; OR  1.35;
95% CI: 1.04 –1.74), model 4 (inflammatory; OR  1.34;
95% CI: 1.04 –1.73), model 5 (lifestyle; OR  1.25; 95%
CI: 0.95–1.64), and model 6 (SES; OR1.26; 95% CI:
0.98 –1.63). We also conducted analyses using CES-D
score as a continuous variable and found very similar
results to the analyses in which CES-D scores were cate-
gorized (16 versus 16). For each 1-point increase in
CES-D, the odds of treated diabetes were: 1.016 (model 1;
p  .004), 1.015 (model 2; p  .015), 1.014 (model 3; p 
.018), 1.015 (model 4; p  .014), 1.013 (model 5; p  .04),
and 1.012 (model 6; p  .05). IFG and untreated diabetes





Depression (CES-D 16 and/or
Antidepressant Medication
Use), n  1224
p*
Age, years 62.4 (10.2) 61.1 (10.4) .002
Ethnicity (%) .001
White 37.8 (n  2090) 41.8 (n  511)
Chinese-American 13.0 (n  719) 6.7 (n  82)
African-American 28.8 (n  1593) 22.0 (n  269)
Hispanic 20.4 (n  1128) 29.6 (n  362)
MESA Site (%) .001
Wake Forest University 16.3 (n  899) 13.6 (n  166)
Columbia University 15.2 (n  843) 20.9 (n  256)
Johns Hopkins University 15.7 (n  872) 14.1 (n  173)
University of Minnesota 15.1 (n  835) 18.8 (n  230)
Northwestern University 17.5 (n  970) 15.6 (n  191)
University of California, Los Angeles 20.1 (n  1111) 17.0 (n  208)
Sex (%) .001
Male 50.7 (n  2805) 31.1 (n  381)
Female 49.3 (n  2725) 68.9 (n  843)
Cigarette smoking status (%) .001
Never 51.0 (n  2810) 48.7 (n  595)
Former 36.7 (n  2025) 35.0 (n  428)
Current 12.3 (n  677) 16.2 (n  198)
Education status (%) .001
Less than high school 17 (n  934) 23 (n  283)
High school 18 (n  992) 19 (n  234)
Some college, technical school, associates’ degree 29 (n  1588) 28 (n  341)
College or greater 36 (n  2011) 30 (n  366)
Annual income $30,000 (%) 35.3 47.0 .001
Daily caloric intake (kcal/day) 1649 (812) 1760 (922) .001
Glucose tolerance categories (%) .001
Normal 57.7 (n  3190) 58.9 (n  721)
Impaired fasting glucose 28.5 (n  1575) 24.8 (n  304)
Untreated diabetes 4.4 (n  246) 3.8 (n  46)
Treated diabetes 9.4 (n  519) 12.5 (n  153)
Systolic blood pressure (mm Hg) 127 (21.3) 127 (23.3) 1.0
Diastolic blood pressure (mm Hg) 72.1 (10.2) 71.3 (10.4) .06
Waist circumference (cm) 97.9 (14.2) 99.2 (15.7) .004
BMI (kg/m2) 28.2 (5.4) 29.0 (5.94) .001
Fasting glucose (mg/dl)b 96.1 (9.7) 95.1 (10.2) .008
Fasting insulin (mIU/L)a,b 5.1 (3.4–7.9) 5.3 (3.4–8.1) .45
HOMA-IR (mmol/L  mIU/L2)a,b 1.18 (0.77–1.9) 1.21 (0.76–1.93) .80
Total cholesterol (mg/dl) 194 (35.5) 196 (36.8) .08
LDL cholesterol (mg/dl) 118 (31.1) 116 (32.7) .04
HDL cholesterol (mg/dl) 50.5 (14.7) 52.7 (15.0) .003
Triglycerides (mg/dl)a 110 (77–159) 118 (81–169) .001
IL-6 (pg/ml) 1.53 (1.20) 1.69 (1.31) .001
CRP (mg/L) 3.63 (5.67) 4.45 (7.05) .001
CES-D  Center for Epidemiologic Studies Depression scale; MESA  multiethnic study of atherosclerosis; BMI  body mass index; HOMA-IR  homeostatic
model assessment of insulin resistance; LDL  low-density lipoprotein; HDL  high-density lipoprotein.
* For categorical covariates, the p value was generated from the 2 test. For continuous covariates, the p value was generated from the analysis of variance
(ANOVA). For the non-normally distributed variables, the p value was generated from the Wilcoxon rank-sum test.
a Summary statistic represents median (interquartile range).
b Summary estimates exclude individuals with diabetes.
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were not associated with either continuous or categorical
CES-D scores.
Table 3 summarizes the results of multivariable linear
regression models in which the CES-D score was modeled as
a continuous variable. CES-D scores were not significantly
different for individuals with IFG (p  .30) and untreated
diabetes (p  .61) compared with those with normal glucose
tolerance (data not shown). However, compared with individ-
uals with normal glucose tolerance, individuals with treated
diabetes had a mean CES-D score that was 0.73 point higher
in the base model that was adjusted for age, sex, race/ethnic-
ity, and MESA site (p  .021). This association remained
significant after adjustment for BMI (mean CES-D score 
0.79 point higher; p  .01). Further adjustment for metabolic
factors (lipids), inflammatory factors (IL-6 and CRP), and
markers of SES (income and education) attenuated this asso-
ciation such they were only of borderline significance (p 
.05, p  .05, p  .06 respectively). The association was most
strongly attenuated after adjustment for lifestyle covariates,
including BMI, caloric intake, and smoking, in which individ-
uals with treated diabetes had a mean CES-D score that was
only 0.36 point higher than individuals with normal glucose
tolerance (p  .30).
In an analysis that excluded individuals with untreated and
treated diabetes, we did not find an association between insu-
lin resistance, estimated by HOMA-IR, and CES-D scores in
either univariate or multivariable linear regression models
(data not shown).
Analyses Exploring the Hypothesis That Diabetes
Leads to Depression
We hypothesized that individuals who were aware of their
diabetes diagnosis or had more severe diabetes, indicated by
the need for insulin or the presence of complications, might be
more likely to be depressed. Among the 292 individuals with
untreated diabetes, only 50 (17%) were aware of their diag-
nosis. The median CES-D scores were not different between
the 50 individuals who were aware of their diagnosis (me-
dian  6; interquartile range: 3–11) and the 242 individuals
who were unaware of their diagnosis (median  5; interquar-
tile range: 2–10) (p  .28 from Wilcoxon rank-sum test).
Among the 653 individuals with treated diabetes, there was no
difference in median CES-D scores between individuals
treated with insulin (median  7; interquartile range: 3–13;
n  117) and individuals treated with oral hypoglycemic
agents (median  6; interquartile range: 2–12; n  536) (p 
.11 from Wilcoxon rank-sum test). In contrast, individuals
with treated diabetes complicated by microalbuminuria had
significantly higher median depression scores (median  7;
interquartile range: 3–13; n  205) than individuals without
microalbuminuria (median  6; interquartile range: 2–11; n 
467) (p  .046 from Wilcoxon rank-sum test).
DISCUSSION
In the MESA study, depression, defined as a CES-D score
of 16 and/or antidepressant medication use, was cross-sec-
TABLE 2. Relative Odds (95% Confidence Interval) of Impaired Fasting Glucose and Diabetes by Depression Status (CES-D Score of >16







Model 1 (base) 1.01 (0.87–1.18) 1.03 (0.74–1.45) 1.57 (1.27–1.96)
Model 2 (BMI) 1.01 (0.86–1.18) 0.98 (0.69–1.39) 1.52 (1.22–1.90)
Model 3 (metabolic) 1.01 (0.86–1.18) 1.05 (0.72–1.45) 1.54 (1.23–1.93)
Model 4 (inflammatory) 1.02 (0.87–1.19) 0.96 (0.67–1.37) 1.53 (1.21–1.92)
Model 5 (lifestyle) 1.00 (0.84–1.78) 1.02 (0.71–1.47) 1.48 (1.16–1.88)
Model 6 (SES) 1.00 (0.85–1.17) 0.92 (0.64–1.32) 1.47 (1.17–1.95)
CES-D  Center for Epidemiologic Studies Depression scale; BMI  body mass index; SES  socioeconomic status; MESA  Multiethnic Study of
Atherosclerosis; HDL  high-density lipoprotein; LDL  low-density lipoprotein; IL  interleukin; CRP  C-reactive protein; Model 1  adjusted for age,
sex, race/ethnicity, and MESA site; Model 2  Model 1  BMI; Model 3 (metabolic)  Model 2  log-transformed triglycerides  HDL cholesterol  LDL
cholesterol; Model 4 (inflammatory)  Model 2  IL-6  CRP; Model 5 (lifestyle)  Model 2  daily caloric intake  smoking status; Model 6 (SES) 
Model 2  education status  annual household income.
* In all of these analyses, individuals without depression were the reference group.
TABLE 3. Mean Difference in CES-D Score (95% Confidence
Interval) in Individuals With Treated Diabetes, Compared With
Individuals With Normal Glucose Tolerance in the Multiethnic Study
of Atherosclerosis
Mean Difference in CES-D Score
(95% CI)
Model 1 (base) 0.73 (0.11–1.36)
Model 2 (BMI) 0.79 (0.16–1.42)
Model 3 (metabolic) 0.66 (0.004–1.32)
Model 4 (inflammatory) 0.64 (0.002–1.28)
Model 5 (lifestyle) 0.36 (0.30–1.03)
Model 6 (SES) 0.60 (0.03–1.24)
CES-D  Center for Epidemiologic Studies Depression scale; CI  confi-
dence interval; BMI  body mass index; SES  socioeconomic status;
MESA  Multiethnic Study of Atherosclerosis; HDL  high-density lipopro-
tein; LDL  low-density lipoprotein; IL  interleukin; CRP  C-reactive
protein; Model 1  adjusted for age, sex, race/ethnicity, and MESA site;
Model 2  Model 1  BMI; Model 3 (metabolic)  Model 2  log-
transformed triglycerides  HDL cholesterol  LDL cholesterol; Model 4
(inflammatory)  Model 2  IL-6  CRP; Model 5 (lifestyle)  Model 2 
daily caloric intake  smoking status; Model 6 (SES)  Model 2  education
status  annual household income.
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tionally associated with a greater odds of having treated dia-
betes but was not associated with IFG or untreated diabetes.
The association of depression with treated diabetes, which was
similar among all race/ethnicities, was not entirely explained
by adiposity, metabolic factors, inflammatory markers, life-
style factors (i.e., daily caloric intake and smoking status), or
markers of SES (i.e., education and income). Among individ-
uals with treated diabetes, the median depression score was
higher among those with microalbuminuria, suggesting that
depression may be more common among those with more
severe diabetes. However, there was no association between
depression scores, measured continuously, and HOMA-IR
among individuals without diabetes.
Our study has several strengths. First, MESA is a large,
ethnically diverse cohort that allowed us to examine race/
ethnicity interactions; to our knowledge, MESA is one of the
largest studies to examine the association of depression and
diabetes by ethnicity. Second, there was standardized ascer-
tainment of glucose tolerance status and diabetes as well as
standardized measurements of depression and behavioral and
physiological explanatory factors in a rigorously monitored
observational study. This allowed us to explore potential ex-
planatory/confounding factors in the association between
depression and diabetes. Third, because individuals with prev-
alent cardiovascular disease were excluded, these results per-
tain to a relatively healthy, population-based sample.
Several limitations should be kept in mind, however, in
interpreting our data. First, this was a cross-sectional study,
which does not allow us to determine the temporality of the
association between depression and diabetes nor causality;
however, the longitudinal structure of MESA will allow for
these types of analyses in the future. Second, there are limi-
tations to using the CES-D scale to assess depression. The
CES-D scale was not designed to measure clinical depression;
it is based on self-report of symptoms and not a psychiatric
diagnosis; and it measures depressive symptoms during a
short period of time, as opposed to lifetime depression. This
scale has been shown, however, to be a valid tool when used
in epidemiological studies (47) and is the most commonly
used short instrument for assessing mild-to-moderate depres-
sion and dysthymia in epidemiological studies conducted in
the United States (48). Third, although the mean CES-D score
was significantly higher by 0.73 point in individuals with
treated diabetes compared with those with normal glucose
tolerance, this finding is of uncertain clinical significance.
Fourth, including antidepressant use in the definition of de-
pression may have misclassified individuals who were taking
antidepressants for other reasons; however, our results were
similar when only CES-D scores were used. Also, a recent
study indicated the utility in using both markers to define
depression as treated individuals may have normal CES-D
scores (49). Fifth, the results of our multivariable models may
have been influenced by univariate prescreening; however,
most of these covariates are established risk factors for dia-
betes. Finally, our ability to assess the severity of diabetes
among individuals with treated diabetes was limited to the
assessment of microalbuminuria as MESA did not have data
on the presence of retinopathy or glycosylated hemoglobin in
the baseline data.
Several studies have shown that depression leads to Type 2
diabetes (3–7) and there are several possible mechanisms that
may explain this association. First, depression is associated
with neurohormonal changes, including activation of the hy-
pothalamic-pituitary-adrenal axis and sympathoadrenal sys-
tem and alteration in the hypothalamic-growth hormone axis.
This leads to an increase in counterregulatory hormones—
cortisol, catecholamines, and growth hormone—which antag-
onize the hypoglycemic effects of insulin, leading to insulin
resistance (50). Second, depression is also associated with
alterations in glucose transport (50). Third, depression leads to
increased inflammatory activation (30,31,50,51) and chronic
cytokinemia can lead to insulin resistance and impaired  cell
function—antecedents to the development of Type 2 diabetes
(51). Fourth, depression may have a negative impact on be-
havioral factors such as dietary intake, physical activity, med-
ication adherence, and smoking, which may increase the risk
for developing Type 2 diabetes. In our study, depressed indi-
viduals had higher caloric intake and were more likely to be
smokers. Other studies have found that depressed individuals
were less compliant with dietary and weight loss recommen-
dations (52) and were more physically inactive and nonadher-
ent to medications (22–25). Finally, antidepressant medication
use is associated with weight gain and obesity (53,54), which
could also predispose depressed individuals to the develop-
ment of Type 2 diabetes.
Our data in MESA suggest that depression may develop in
individuals with diagnosed and treated diabetes as we did not
see an association of depression with prediabetes (IFG) and
we did not see an association between depression and insulin
resistance in nondiabetic individuals in the MESA cohort. In
accordance with previous studies (55,56), we found that de-
pression was not associated with untreated diabetes. The tem-
poral relationship between depression and diabetes needs to be
confirmed through longitudinal follow-up of the MESA
cohort.
In addition, individuals with treated diabetes who had
evidence of a complication of diabetes, microalbuminuria, had
slightly higher depression scores, suggesting that depression
may be related to the severity of diabetes. A previous study of
individuals with diabetes also found that depression was as-
sociated with nephropathy (57). Other diabetic complications
associated with depression include macrovascular disease
(11,58), retinopathy (15,59), and neuropathy (60,61). Depres-
sion is more likely to occur with the development of new
diabetic complications and in the setting of multiple diabetic
complications, particularly those associated with impaired vi-
sual, physical, and cognitive functioning and those associated
with the development of sexual dysfunction (1). Although
some studies have not found an association between the num-
ber of diabetic complications and an increased prevalence of
depression (13,62–65), many others have found that individ-
uals with a greater number of complications (11,22,23,66–69)
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and comorbid conditions (56) are more likely to be depressed.
Depression has also been associated with hyperglycemia in
individuals with diabetes (70), suggesting that there may be a
physiological association between depression and diabetes as
well as a psychological association.
In the MESA cohort, the association between depression
and treated diabetes was only partially explained by lifestyle
factors (daily caloric intake and smoking status). In our study,
individuals with depression were more likely to be current
smokers and to have greater daily caloric intake. Diabetic
individuals with depression have been shown to have poor
adherence to medical and dietary regimens (22–25), a higher
attrition rate in a behavioral weight loss intervention program
(52), and higher prevalence of smoking (71). This suggests
that depression can have a negative impact on health behav-
iors in individuals who already have diabetes, leading to poor
metabolic control and an increased risk of developing com-
plications, or this suggests that poor health behaviors may
exacerbate depression. Intervention trials of depression treat-
ment in individuals with diabetes have shown improvement in
glycemic control with resolution of depressive symptoms
(70,72).
The association between depression and treated diabetes
was also attenuated by markers of SES (education and annual
income), although the association remained statistically sig-
nificant. In the MESA cohort, depressed individuals were less
likely to have completed college and were more likely to have
a high school education or less and to report an annual income
of $30,000. Several studies have shown that lower SES is
associated with a greater likelihood of depression among
individuals with diabetes (10,13,22,67). A recent study found
that depression was more common in diabetic individuals with
less than a high school education (18). Carnethon et al. found
that depression predicted diabetes only among individuals
with less than a high school education (5). It is hypothesized
that individuals with lower SES and limited financial re-
sources may be more likely to engage in adverse health
behaviors that may worsen metabolic control in diabetes (5).
Despite differences in the prevalence of depression by
race/ethnicity, we did not find that the association between
depression and treated diabetes varied by the ethnicities in-
cluded in the MESA study. These results are similar to other
studies, which have found that depression among diabetic
individuals did not vary by race (17–19), suggesting that all
populations with diabetes are at risk for having comorbid
depression.
The main implication of our study is that longitudinal
analyses are needed to confirm whether diagnosed diabetes
leads to incident depression. The structure of subsequent
MESA examinations will permit these types of analyses. Our
study also suggests that individuals with treated diabetes who
have evidence of diabetic complications should be assessed
and treated for depression and have interventions directed at
behavior modifications and removal of socioeconomic barri-
ers that will prevent worsening of metabolic control and
clinical outcomes.
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